Paper Details

  1. Home
  2. Paper Details

Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.

Author: GlidewellO, RaiK R, SawitskyA, SilverR T

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

A study of 96 patients with stage III and stage IV chronic lymphocytic leukemia found that prednisone plus chlorambucil was more effective than prednisone alone, but there was no significant difference in overall survival between the three treatment schedules.
Paper Details　
Original Abstract of the Article :
Ninety-six patients with stage III and stage IV chronic lymphocytic leukemia (CLL) were randomized into one of three treatment schedules. Prednisone was common to all three schedules and was given daily in an initial dosage of 0.8 mg/kg for the first 14 days, with successive halving of the daily dos...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/336116

データ提供：米国国立医学図書館（NLM）

Chronic Lymphocytic Leukemia: A Comparative Study of Chlorambucil Regimens

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the white blood cells. This study investigates the effectiveness and safety of different treatment schedules for CLL, comparing daily versus intermittent chlorambucil therapy in combination with prednisone. The study aims to identify the most effective and tolerable treatment regimen for patients with stage III and stage IV CLL.

Tailoring Treatment: Finding the Right Path for CLL Patients

The study shows that both daily and intermittent chlorambucil regimens, in combination with prednisone, were effective in inducing remission in patients with CLL. However, the intermittent chlorambucil schedule demonstrated longer survival for patients who achieved remission. The study also highlights the minimal toxicity associated with both treatment regimens, emphasizing the importance of selecting a treatment plan that balances effectiveness with tolerability.

Navigating CLL Treatment: A Personalized Approach

The study underscores the importance of a personalized approach to CLL treatment. It highlights the need for careful consideration of individual patient factors, including disease stage, response to treatment, and tolerance to medications. The study emphasizes the importance of ongoing research to develop more effective and targeted treatments for CLL, improving outcomes and quality of life for patients.

Dr.Camel's Conclusion

This study offers valuable insights into the effectiveness and safety of different treatment schedules for CLL. The findings suggest that intermittent chlorambucil therapy may be a more effective option for patients with stage III and stage IV CLL. The study highlights the importance of individualized treatment plans and the need for continued research to improve treatment outcomes for CLL patients.

Date :
  1. Date Completed 1978-01-27
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

336116

DOI: Digital Object Identifier

S0006-4971(20)75637-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.